FY2026 EPS Estimate for Immunovant Increased by Analyst

Immunovant, Inc. (NASDAQ:IMVT) – Investment analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Immunovant in a research report issued to clients and investors on Tuesday, February 10th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($2.66) per share for the year, up from their previous forecast of ($3.04). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Immunovant’s Q4 2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($0.66) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at $0.03 EPS.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a report on Friday, January 9th. The Goldman Sachs Group boosted their target price on Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Wolfe Research raised shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research note on Tuesday, January 6th. Truist Financial lifted their price objective on shares of Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Finally, Guggenheim lifted their price target on shares of Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.11.

Immunovant Stock Performance

Shares of Immunovant stock opened at $25.64 on Friday. Immunovant has a 52 week low of $12.72 and a 52 week high of $27.92. The stock has a market capitalization of $5.22 billion, a price-to-earnings ratio of -9.53 and a beta of 0.54. The firm has a fifty day moving average of $25.92 and a two-hundred day moving average of $20.99.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings results on Friday, February 6th. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.11. During the same quarter in the prior year, the firm posted ($0.76) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Immunovant by 8.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock worth $708,000 after acquiring an additional 3,348 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Immunovant by 48.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock valued at $17,222,000 after purchasing an additional 329,354 shares during the period. Strs Ohio acquired a new position in shares of Immunovant during the 1st quarter worth approximately $27,000. Aberdeen Group plc raised its position in shares of Immunovant by 3.1% in the second quarter. Aberdeen Group plc now owns 844,705 shares of the company’s stock valued at $13,515,000 after buying an additional 25,228 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in shares of Immunovant by 5.5% in the second quarter. TD Asset Management Inc now owns 192,506 shares of the company’s stock valued at $3,080,000 after buying an additional 10,108 shares during the period. Institutional investors and hedge funds own 47.08% of the company’s stock.

Insider Buying and Selling

In other news, Director Andrew J. Fromkin sold 22,249 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $23.25, for a total value of $517,289.25. Following the completion of the sale, the director directly owned 85,852 shares of the company’s stock, valued at $1,996,059. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CTO Jay S. Stout sold 1,977 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $26.03, for a total value of $51,461.31. Following the transaction, the chief technology officer directly owned 197,634 shares in the company, valued at $5,144,413.02. The trade was a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 63,868 shares of company stock valued at $1,538,470. Insiders own 1.80% of the company’s stock.

Key Immunovant News

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and annual EPS forecasts for Immunovant, trimming expected losses across 2026–2028 and projecting a small positive EPS of $0.03 in FY2029 (up from -$0.36). The firm also increased FY2030 to $2.91 and kept a “Buy” rating with a $35 price target — a clear analyst vote of confidence that the company’s path to profitability may be sooner than previously modeled. Article Title
• Neutral Sentiment: HC Wainwright specifically tightened quarterly EPS estimates (examples: Q1–Q4 2026/2027 and Q3 2027 revised from about -$0.90 to -$0.62 in some quarters), reflecting improved modeled revenue/cost assumptions — this is constructive but remains forecast-based (not yet realized results). Article Title
• Neutral Sentiment: Short‑interest reports show an anomalous increase with values reported as 0 shares/NaN changes — appears to be a data/reporting glitch rather than a meaningful short‑selling signal; investors should treat these filings cautiously until clarified by exchanges or filings.
• Neutral Sentiment: Context: Immunovant recently beat the prior quarter’s EPS consensus (reported -$0.61 vs. -$0.72 est.), and consensus full‑year estimates still reflect losses (~-$2.69). Analyst upgrades improve the tone, but the company remains in a loss‑making phase where clinical/regulatory and commercialization execution will ultimately drive the stock.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.